Transjugular intrahepatic portosystemic shunt with radioactive seed strand for main portal vein tumor thrombosis with cirrhotic portal hypertension

doi:10.4240/wjgs.v14.i6.567

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4837)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-5) series.

Item

Count

PDF

207

WORD

HTML

1751

Figures (1-4)

347

Tables (1-5)

207

Sum=2585

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

238

Download

442

Sum=680

Publishing Process of This Article

Item

Count

Browse

380

Download

1192

Sum=1572

Jun 27, 2022 (publication date) through Oct 2, 2024

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Surgery

ISSN

1948-9366

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Gastrointest Surg. Jun 27, 2022; 14(6): 567-579
Published online Jun 27, 2022. doi: 10.4240/wjgs.v14.i6.567

Table 1 Baseline characteristics of patients

Characteristics	n (%)/mean ± SD/M (P₂₅-P₇₅)
Gender (male/female)	70/13 (84.3/15.7)
Age (yr)	56.46 ± 8.97
BMI	22.83 ± 2.99
Etiology of cirrhosis (HBV/HCV/alcoholic/other)	66/8/4/5 (79.5/9.6/4.8/6.0)
Cirrhosis-related decompensated events (EGVB/Refractory ascites or hydrothorax/Both)	62/14/7 (74.7/16.9/8.4)
EGV degree (mild/moderate/severe)	7/36/40 (8.4/43.4/48.2)
Ascites degree (no/mild/moderate-severe)	8/24/51 (9.6/28.9/61.4)
Preoperative HVPG (mmHg)	19.96 ± 9.01
Child–Pugh grade (A/B/C)	23/52/8 (27.7/62.7/9.6)
Intrahepatic HCC morphology (unifocal/multifocal)	47/36 (56.6/43.4)
Sum of longest viable tumor diameters (cm)	6.62 ± 2.77
≤ 5/5-8/> 8	23/44/16 (27.7/53.0/19.3)
BCLC stage (C/D)	75/8 (90.4/9.6)
cTNM stage (IIIB/IVA/IVB)	55/19/9 (66.3/22.9/10.8)
PLT (10⁹/L)	108.24 ± 86.09
PT (s)	14.89 ± 3.89
ALT (U/L)	31.40 ± 29.29
AST (U/L)	49.63 ± 45.00
TBil (μmol/L)	31.74 ± 17.68
Albumin (g/L)	35.08 ± 4.85
AFP (ng/mL)¹	769.49 (16.69-2345.11)
Log₁₀(AFP)	2.40 ± 1.26
Combined TACE/RFA/targeted therapy	83/52/41 (100/62.7/49.4)

¹Skewness distribution. The upper limit of AFP detection is 20000 ng/mL. BMI: Body mass index; HBV: Hepatitis B virus; HCV: Hepatitis C virus; EGVB: Esophagogastric variceal bleeding; EGV: Esophagogastric varices; HVPG: Hepatic venous pressure gradient; HCC: Hepatocellular carcinoma; PLT: Platelet; PT: Prothrombin time; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; TBil: Total bilirubin; AFP: Alpha-fetoprotein; TACE: Transarterial chemoembolization; RFA: Radiofrequency ablation.

Citation: Yan XH, Yue ZD, Zhao HW, Wang L, Fan ZH, Wu YF, Meng MM, Zhang K, Jiang L, Ding HG, Zhang YN, Yang YP, Liu FQ. Transjugular intrahepatic portosystemic shunt with radioactive seed strand for main portal vein tumor thrombosis with cirrhotic portal hypertension. World J Gastrointest Surg 2022; 14(6): 567-579
URL: https://www.wjgnet.com/1948-9366/full/v14/i6/567.htm
DOI: https://dx.doi.org/10.4240/wjgs.v14.i6.567